BATON ROUGE, La., Sept. 29, 2017 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, is pleased to announce that it has successfully achieved development milestones in formulation and stability with tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL).  OncBioMune owns the commercialization rights for tretinoin throughout Mexico, Central America and Latin America.

PROCAPS S.A.S., the Company’s contract manufacturing organization, is currently in the midst of manufacturing the first batch of tretinoin from its state-of-the-art cGMP facility in Colombia.  OncBioMune has been advised that production remains on schedule for the planned product launch scheduled in 2018.

“Achieving development milestones with PROCAPS has us now making preparations for the tretinoin launch in Mexico early next year and subsequently into Central and Latin America where APL remains problematic,” commented Andrew Kucharchuk, President at OncBioMune.  “To have a partner like PROCAPS with their experience and leading production facility is invaluable in meeting our high standards on time and within budget.”

There are currently no approved drugs in Mexico for the treatment of APL, an aggressive type of Acute Myeloid Leukemia in which there are too many immature blood-forming cells in the blood and bone marrow, which leads to a shortage of healthy white and red blood cells and platelets.  In developed countries, APL is regarded as one of the more curable types of leukemia, with tretinoin a commonly prescribed part of the therapeutic regimen.  However, little therapeutic progress has been made in developing countries to deliver a measurable benefit with respect to complete hematological remission and disease-free survival, as is highly possible with tretinoin in the treatment protocol.

Based upon these facts, OncBioMune believes it can emerge as a market leader in the treatment of APL in Mexico, Central and South America.  Early financial models have the company expecting to generate approximately US$300,000 in revenue during the launch year and approximately US$750,000 in the first full year (2019) for only the Mexican Market.

Sign up for OncBioMune email alerts at:

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer